TDMS Study 05165-02 Pathology Tables
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
Facility: Battelle Columbus Laboratory
Chemical CAS #: 96-69-5
Lock Date: 01/10/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 9 9 10 10
Early Deaths
Natural Death 7 9 11 11
Moribund Sacrifice 4 3 3 4
Survivors
Natural Death 1
Terminal Sacrifice 39 38 36 35
Missing 1
Animals Examined Microscopically 60 59 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (59) (59) (60) (60)
Gallbladder (59) (57) (58) (57)
Intestine Large, Colon (59) (59) (60) (60)
Leiomyosarcoma 1 (2%)
Intestine Large, Rectum (59) (59) (60) (60)
Intestine Large, Cecum (59) (59) (60) (60)
Intestine Small, Duodenum (59) (59) (60) (60)
Intestine Small, Jejunum (59) (59) (60) (60)
Serosa, Fibrosarcoma, Metastatic, Skin 1 (2%)
Liver (60) (59) (60) (60)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Fibrous Histiocytoma, Multiple, Metastatic,
Mesentery 1 (2%)
Hepatocellular Carcinoma 3 (5%) 7 (12%) 7 (12%) 4 (7%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 14 (23%) 11 (19%) 11 (18%) 10 (17%)
Hepatocellular Adenoma, Multiple 6 (10%) 7 (12%) 7 (12%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Mesentery (5) (6) (4) (1)
Fibrous Histiocytoma 1 (17%)
Fat, Fibrosarcoma, Metastatic, Skin 1 (17%)
Fat, Granulosa-Theca Tumor Malignant,
Metastatic, Ovary 1 (20%)
Fat, Histiocytic Sarcoma, Metastatic, Uterus 1 (25%)
Pancreas (59) (59) (59) (60)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Serosa, Fibrosarcoma, Metastatic, Skin 1 (2%)
Page 2
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Salivary Glands (60) (59) (57) (60)
Stomach, Forestomach (59) (59) (60) (60)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Papilloma 2 (3%)
Stomach, Glandular (59) (59) (60) (60)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (59) (60) (60)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (59) (60) (60)
Sarcoma, Metastatic, Kidney 1 (2%)
Capsule, Fibrosarcoma, Metastatic, Skin 1 (2%)
Capsule, Spindle Cell, Adenoma 1 (2%)
Spindle Cell, Subcapsular, Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (58) (59) (60) (60)
Pheochromocytoma Benign 2 (3%) 2 (3%) 2 (3%)
Bilateral, Pheochromocytoma Malignant 1 (2%)
Pituitary Gland (57) (58) (59) (58)
Pars Distalis, Adenoma 5 (9%) 6 (10%) 9 (15%) 4 (7%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Pars Intermedia, Carcinoma 1 (2%)
Thyroid Gland (60) (59) (59) (60)
Follicular Cell, Adenoma 1 (2%) 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Fibrosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (59) (59) (60)
Cystadenoma 3 (5%) 3 (5%) 2 (3%)
Granulosa-Theca Tumor Malignant 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Page 3
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Luteoma 2 (3%)
Sarcoma 1 (2%)
Teratoma Benign 2 (3%)
Thecoma Benign 1 (2%)
Periovarian Tissue, Histiocytic Sarcoma 1 (2%)
Uterus (60) (59) (60) (60)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 3 (5%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (3%) 1 (2%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (59) (60) (60)
Femoral, Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (9) (7) (4) (7)
Lumbar, Fibrous Histiocytoma, Metastatic,
Uncertain Primary Site 1 (25%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (14%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Uncertain Primary Site 1 (25%)
Mediastinal, Histiocytic Sarcoma 1 (11%)
Pancreatic, Histiocytic Sarcoma 1 (11%)
Pancreatic, Histiocytic Sarcoma, Metastatic,
Uterus 1 (25%)
Renal, Fibrous Histiocytoma, Metastatic,
Uncertain Primary Site 1 (25%)
Renal, Granulosa-Theca Tumor Malignant,
Metastatic, Ovary 1 (11%) 1 (14%)
Renal, Sarcoma, Metastatic, Kidney 1 (14%)
Lymph Node, Mandibular (59) (59) (57) (60)
Granulosa-Theca Tumor Malignant, Metastatic,
Ovary 1 (2%)
Lymph Node, Mesenteric (52) (51) (51) (52)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Granulosa-Theca Tumor Malignant, Metastatic,
Ovary 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Spleen (60) (59) (60) (59)
Hemangiosarcoma 2 (3%) 1 (2%) 1 (2%)
Thymus (55) (52) (54) (58)
Page 4
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (59) (59) (58) (59)
Adenocarcinoma, Multiple 1 (2%)
Skin (60) (59) (60) (60)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (3%) 2 (3%) 3 (5%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma,
Metastatic, Skin 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma,
Metastatic, Uncertain Primary Site 1 (2%)
Subcutaneous Tissue, Hemangioma 2 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (60) (59) (60) (60)
Diaphragm, Fibrous Histiocytoma, Metastatic,
Mesentery 1 (2%)
Diaphragm, Granulosa-Theca Tumor Malignant,
Metastatic, Ovary 1 (2%)
Thigh, Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Thigh, Histiocytic Sarcoma, Metastatic,
Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (59) (60) (60)
Histiocytic Sarcoma 1 (2%)
Meninges, Cerebrum, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (59) (60) (60)
Alveolar/Bronchiolar Adenoma 2 (3%) 3 (5%) 1 (2%) 3 (5%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Granulosa-Theca Tumor Malignant, Metastatic,
Ovary 1 (2%)
Page 5
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 3 (5%) 3 (5%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (2) (1)
Adenoma 1 (50%)
Pinna, Fibroma 1 (50%)
Eye (1) (1) (1)
Adenocarcinoma, Metastatic, Harderian Gland 1 (100%)
Harderian Gland (1) (3) (1) (1)
Adenocarcinoma 1 (100%) 2 (67%)
Adenoma 1 (33%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (59) (60) (60)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Sarcoma 1 (2%)
Urinary Bladder (59) (59) (60) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(59) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 4 (7%)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Lymphoma Malignant Lymphocytic 3 (5%) 2 (3%) 5 (8%) 5 (8%)
Lymphoma Malignant Mixed 7 (12%) 4 (7%) 4 (7%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 38 39 41
Total Primary Neoplasms 64 65 66 48
Total Animals with Benign Neoplasms 30 31 25 25
Total Benign Neoplasms 37 38 39 29
Total Animals with Malignant Neoplasms 23 22 23 18
Total Malignant Neoplasms 27 27 27 19
Total Animals with Metastatic Neoplasms 5 6 6 2
Total Metastatic Neoplasm 8 16 21 5
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 6 6 1 4
Moribund Sacrifice 2 2 1
Survivors
Natural Death 1 1
Terminal Sacrifice 41 41 49 45
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (60) (59) (60) (59)
Intestine Small, Duodenum (60) (59) (59) (60)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (60)
Adenocarcinoma 1 (2%)
Liver (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 8 (13%) 9 (15%) 7 (12%) 3 (5%)
Hepatocellular Carcinoma, Multiple 3 (5%) 2 (3%) 3 (5%) 1 (2%)
Hepatocellular Adenoma 11 (18%) 13 (22%) 20 (33%) 10 (17%)
Hepatocellular Adenoma, Multiple 6 (10%) 11 (18%) 6 (10%) 4 (7%)
Mesentery (1) (2) (1)
Pancreas (60) (60) (60) (60)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Bilateral, Spindle Cell, Subcapsular, Adenoma 1 (2%) 1 (2%)
Capsule, Spindle Cell, Adenoma 1 (2%)
Spindle Cell, Subcapsular, Adenoma 11 (18%) 6 (10%) 6 (10%) 6 (10%)
Adrenal Medulla (60) (60) (60) (60)
Page 8
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (55) (56) (58) (57)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Adenocarcinoma 1 (2%)
C-Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Testes (60) (60) (60) (60)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (58)
Femoral, Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (1) (1) (2)
Inguinal, Hemangioma 1 (100%)
Lymph Node, Mandibular (59) (57) (57) (58)
Lymph Node, Mesenteric (58) (55) (58) (55)
Fibrosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Spleen (60) (60) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Thymus (56) (56) (56) (54)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Harderian Gland 2 (3%)
Alveolar/Bronchiolar Adenoma 5 (8%) 7 (12%) 9 (15%) 3 (5%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 2 (3%) 1 (2%)
Fibrosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (5%) 4 (7%) 4 (7%) 1 (2%)
Nose (60) (60) (60) (58)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1)
Pinna, Fibroma 1 (100%)
Pinna, Trichoepithelioma 1 (100%)
Eye (2) (2) (1)
Adenocarcinoma, Metastatic, Harderian Gland 1 (50%)
Harderian Gland (3) (4) (3)
Adenocarcinoma 2 (67%) 1 (33%)
Adenoma 1 (33%) 3 (75%) 2 (67%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Artery, Fibrosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Page 10
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 2 (3%) 3 (5%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/10/95
Route: DOSED FEED Time: 16:17:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 41 45 27
Total Primary Neoplasms 62 61 67 36
Total Animals with Benign Neoplasms 31 32 38 20
Total Benign Neoplasms 41 45 49 23
Total Animals with Malignant Neoplasms 17 15 16 11
Total Malignant Neoplasms 21 16 18 13
Total Animals with Metastatic Neoplasms 5 5 4 1
Total Metastatic Neoplasm 7 7 4 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------